Badanie trimoduliny u dorosłych pacjentów hospitalizowanych z ciężkim zapaleniem płuc

Severe community-acquired pneumonia is a serious lung infection that people can get outside of hospitals. This study is looking at a treatment called Trimodulin, which is a solution made from human proteins that help the immune system. The study will compare the effects of Trimodulin to a placebo, which is a solution that does not contain active medicine. Both treatments are given through a drip into a vein, known as an intravenous infusion.

The main goal of the study is to see if Trimodulin can reduce the number of deaths within 28 days compared to the placebo. The study will involve adults who are in the hospital with severe pneumonia. Participants will receive either Trimodulin or the placebo shortly after they start needing help to breathe with a machine. The study will monitor participants for changes in their health over time, including how long they need breathing support and their overall recovery.

This research is important to find out if Trimodulin can be a better treatment option for people with severe pneumonia. The study will collect information on how well the treatment works and any side effects that might occur. This will help doctors understand if Trimodulin can improve outcomes for patients with this serious condition.